Business Segment Information

6 Months Ended

Aug. 03, 2024

Segment Reporting [Abstract]

Business Segment Information

Note 8

Business Segment Information

Three Months Ended August 3, 2024
(In thousands)	Journeys Group			Schuh Group		Johnston & Murphy Group			Genesco Brands Group			Corporate & Other			Consolidated
Sales	$	298,846		$	124,561	$	71,037		$	30,755		$	—		$	525,199
Intercompany sales elimination		—			—		—			(11	)		—			(11	)
Net sales to external customers(1)		298,846			124,561		71,037			30,744			—			525,188
Segment operating income (loss)		(11,151	)		7,339		(403	)		2,672			(7,953	)		(9,496	)
Asset impairments and other(2)		—			—		—			—			778			778
Operating income (loss)		(11,151	)		7,339		(403	)		2,672			(8,731	)		(10,274	)
Other components of net periodic benefit cost		—			—		—			—			86			86
Interest expense, net		—			—		—			—			1,345			1,345
Earnings (loss) from continuing operations before income taxes	$	(11,151	)	$	7,339	$	(403	)	$	2,672		$	(10,162	)	$	(11,705	)
Total assets (3)	$	668,528		$	205,488	$	157,936		$	80,954		$	270,845		$	1,383,751
Depreciation and amortization		8,540			1,849		1,394			331			1,055			13,169
Capital expenditures		4,313			1,764		1,461			304			55			7,897

(1) Net sales in North America and in the U.K., which includes the ROI, accounted for 76% and 24%, respectively, of our net sales in the second quarter of Fiscal 2025.

(2) Asset impairments and other includes a $0.1 million charge for asset impairments in Journeys Group and $0.7 million for severance.

(3) Of our $631.8 million of long-lived assets, $92.1 million and $11.0 million relate to long-lived assets in the U.K. and Canada, respectively.

Note 8

Business Segment Information, Continued

Three Months Ended July 29, 2023
(In thousands)	Journeys Group			Schuh Group		Johnston & Murphy Group			Genesco Brands Group			Corporate & Other			Consolidated
Sales	$	287,275		$	122,799	$	77,788		$	35,461		$	—		$	523,323
Intercompany sales elimination		—			—		(3	)		(293	)		—			(296	)
Net sales to external customers(1)		287,275			122,799		77,785			35,168			—			523,027
Segment operating income (loss)		(14,878	)		8,416		2,666			1,851			(8,055	)		(10,000	)
Goodwill impairment (2)		—			—		—			—			28,453			28,453
Asset impairments and other (3)		—			—		—			—			174			174
Operating income (loss)		(14,878	)		8,416		2,666			1,851			(36,682	)		(38,627	)
Other components of net periodic benefit cost		—			—		—			—			148			148
Interest expense, net		—			—		—			—			2,383			2,383
Earnings (loss) from continuing operations before income taxes	$	(14,878	)	$	8,416	$	2,666		$	1,851		$	(39,213	)	$	(41,158	)
Total assets (4)	$	769,844		$	218,913	$	187,379		$	56,977		$	261,646		$	1,494,759
Depreciation and amortization		7,810			1,624		1,137			201			1,061			11,833
Capital expenditures		11,193			3,845		2,097			623			305			18,063

(1) Net sales in North America and in the U.K., which includes the ROI, accounted for 77% and 23%, respectively, of our net sales for the second quarter of Fiscal 2024.

(2) Goodwill impairment of $28.5 million is related to Genesco Brand Group.

(3) Asset impairments and other includes a $0.2 million charge for asset impairments in Journeys Group.

(4) Of our $720.8 million of long-lived assets, $94.4 million and $14.7 million relate to long-lived assets in the U.K. and Canada, respectively.

Six Months Ended August 3, 2024
(In thousands)	Journeys Group			Schuh Group		Johnston & Murphy Group		Genesco Brands Group		Corporate & Other			Consolidated
Sales	$	558,291		$	216,910	$	150,244	$	55,354	$	—		$	980,799
Intercompany sales elimination(1)		—			—		—		1,986		—			1,986
Net sales to external customers(2)		558,291			216,910		150,244		57,340		—			982,785
Segment operating income (loss)		(29,973	)		1,443		1,952		1,686		(16,154	)		(41,046	)
Asset impairments and other(3)		—			—		—		—		1,356			1,356
Operating income (loss)		(29,973	)		1,443		1,952		1,686		(17,510	)		(42,402	)
Other components of net periodic benefit cost		—			—		—		—		195			195
Interest expense, net		—			—		—		—		2,235			2,235
Earnings (loss) from continuing    operations before income taxes	$	(29,973	)	$	1,443	$	1,952	$	1,686	$	(19,940	)	$	(44,832	)
Depreciation and amortization	$	17,160		$	3,718	$	2,778	$	645	$	2,105		$	26,406
Capital expenditures		7,804			2,497		3,176		535		262			14,274

(1) Intercompany sales for the first six months of Fiscal 2025 reflect net intercompany returns.

(2) Net sales in North America and in the U.K., which includes the ROI, accounted for 78% and 22%, respectively, of our net sales in the first six months of Fiscal 2025.

(3) Asset impairments and other includes a $0.4 million charge for asset impairments in Journeys Group and $1.0 million for severance.

Note 8

Business Segment Information, Continued

Six Months Ended July 29, 2023
(In thousands)	Journeys Group			Schuh Group		Johnston & Murphy Group			Genesco Brands Group			Corporate & Other			Consolidated
Sales	$	559,465		$	215,904	$	160,418		$	71,325		$	—		$	1,007,112
Intercompany sales elimination		—			—		(6	)		(747	)		—			(753	)
Net sales to external customers(1)		559,465			215,904		160,412			70,578			—		$	1,006,359
Segment operating income (loss)		(33,240	)		6,626		7,472			1,819			(15,366	)	$	(32,689	)
Goodwill impairment(2)		—			—		—			—			28,453			28,453
Asset impairments and other(3)		—			—		—			—			482			482
Operating income (loss)		(33,240	)		6,626		7,472			1,819			(44,301	)		(61,624	)
Other components of net periodic benefit cost		—			—		—			—			240			240
Interest expense		—			—		—			—			4,034			4,034
Earnings (loss) from continuing    operations before income taxes	$	(33,240	)	$	6,626	$	7,472		$	1,819		$	(48,575	)	$	(65,898	)
Depreciation and amortization	$	15,157		$	3,185	$	2,257		$	404		$	2,116		$	23,119
Capital expenditures		24,212			5,996		3,302			1,078			710			35,298

(1) Net sales in North America and in the U.K., which includes the ROI, accounted for 79% and 21%, respectively, of our net sales for the first six months of Fiscal 2024.

(2) Goodwill impairment of $28.5 million is related to Genesco Brand Group.

(3) Asset impairments and other includes a $0.5 million charge for asset impairments in Journeys Group.